What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: Overview and investigational topical agents

Cutis

Volumn 89, Issue 5, 2012, Pages 241-250

  Berman, Brian ^a,b   Cohen, David E ^c   Amini, Sadegh ^b  

^a Center for Clinical and Cosmetic Research   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIC KERATOSIS; DISEASE COURSE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVIEW; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, CUTANEOUS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; HUMANS; KERATOSIS, ACTINIC; MEDICATION ADHERENCE; PATIENT SATISFACTION; SKIN NEOPLASMS;

EID: 84864098237     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol. 2006;5:167-173.
2. de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses [published correction in Br J Dermatol. 2008;158:873]. Br J Dermatol. 2007;156:222-230.
3. Stern RS. Dermatologists and office-based care of dermatologic disease in the 21st century. J Investig Dermatol Symp Proc. 2004;9:126-130.
4. Warino L, Tusa M, Camacho F, et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006;32:1045-1049.
5. Berman B, Bienstock L, Kuritizky L, et al; Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratosis: sequelae and treatments. recommendations from a consensus panel. J Fam Pract. 2006;55(suppl):1-8.
6. Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities [published online ahead of print March 13, 2008]. Br J Dermatol. 2008;158:994-999.
7. Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol. 2003;139:1313-1320.
8. Leffell D. New advances in treating actinic keratoses. Skin & Aging. 2002;10:31-32.
9. Weinstock MA, Bingham SF, Cole GW, et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol. 2001;137:1055-1058.
10. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649-655.
11. Schwartz RA. The actinic keratosis. a perspective and update. Dermatol Surg. 1997;23:1009-1019.
12. Ulrich M, Krueger-Corcoran D, Roewert-Huber J, et al. Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses [published online ahead of print November 11, 2009]. Dermatology. 2010;220:15-24.
13. Jeffes EW 3rd, Tang EH. Actinic keratosis. current treatment options. Am J Clin Dermatol. 2000;1:167-179.
14. Horn M, Gerger A, Ahlgrimm-Siess V, et al. Discrimination of actinic keratoses from normal skin with reflectance mode confocal microscopy. Dermatol Surg. 2008;34:620-625.
15. Ulrich M, Maltusch A, Röwert-Huber J, et al. Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol. 2007;156(suppl 3):13-17.
16. Sanmartin O, Guillen C. Images in clinical medicine. fluorescence diagnosis of subclinical actinic keratoses. N Engl J Med. 2008;358:e21.
17. Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol. 2003;149(suppl 66):37-39.
18. Burkhart CG. Reports of immunologic reactions to imiquimod: an assessment of actinic keratoses and treatment concerns in this era of litigation lotto. Dermatol Online J. 2005;11:40.
19. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1, pt 2):4-7.
20. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975-983.
21. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16:335-339.
22. Helfand M, Gorman AK, Mahon S, et al. Actinic keratoses: final report. Portland, OR: Oregon Health and Science University Evidence-Based Practice Center; 2001. http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&ID=12003008003. Accessed April 3, 2012.
23. Dinehart SM, Nelson-Adesokan P, Cockerell C, et al. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer. 1997;79:920-923.
24. Stockfleth E, Kerl H; Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16:599-606.
25. Stern RS. Clinical practice. treatment of photoaging. N Engl J Med. 2004;350:1526-1534.
26. Nora AB, Panarotto D, Lovatto L, et al. Frequency of counseling for skin cancer prevention by the various specialties in Caxias do Sul. An Bras Dermatol. 2004;79:45-52.
27. Black HS, Herd JA, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med. 1994;330:1272-1275.
28. Hughes MC, Williams GM, Fourtanier A, et al. Food intake, dietary patterns, and actinic keratoses of the skin: a longitudinal study [published online ahead of print February 25, 2009]. Am J Clin Nutr. 2009;89:1246-1255.
29. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25:231-240.
30. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 1999;20:1939-1944.
31. Tang X, Kim AL, Kopelovich L, et al. Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice [published online ahead of print February 2, 2008]. Photochem Photobiol. 2008;84:522-527.
32. Butler GJ, Neale R, Green AC, et al. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin [published online ahead of print October 19, 2005]. J Am Acad Dermatol. 2005;53:966-972.
33. Stockfleth E, Ferrandiz C, Grob JJ, et al; for the European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European consensus [published online ahead of print October 27, 2008]. Eur J Dermatol. 2008;18:651-659.
34. Balkrishnan R, Cayce KA, Kulkarni AS, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat. 2006;17:162-166.
35. Spencer JM, Hazan C, Hsiung SH, et al. Therapeutic decision making in the therapy of actinic keratoses. J Drugs Dermatol. 2005;4:296-301.
36. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. committee on guidelines of care. J Am Acad Dermatol. 1995;32:95-98.
37. American Academy of Dermatology. Treatment options. ActinicKeratosesNet. http://www.skincarephysicians.com/actinickeratosesnet/treatmentoptions.html. Published 2010. Accessed April 2, 2012.
38. Chia A, Moreno G, Lim A, et al. Actinic keratoses. Aust Fam Physician. 2007;36:539-543.
39. Del Rosso JQ. New and emerging topical approaches for actinic keratoses. Cutis. 2003;72:273-276, 279.
40. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-721.
41. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil 0.5% cream for the treatment of actinic keratosis. Arch Dermatol. 2009;145:203-205.
42. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64:2833-2839.
43. Challacombe JM, Suhrbier A, Parsons PG, et al. ?Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177:8123-8132.
44. Ersvaer E, Kittang AO, Hampson P, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity [published online ahead of print January 22, 2010]. Toxins (Basel). 2010;2:174-194.
45. Hampson P, Wang K, Lord JM. PEP-005. Treatment of actinic keratoses, acute myeloid leukemia therapy, treatment of basal cell carcinoma, protein kinase C activator. Drugs Future. 2005;30:1003-1005.
46. Anderson L, Wellburn P. Maximum tolerated dose of PEP005 topical gel for the treatment of actinic keratosis. poster P1503. Poster presented at: American Academy of Dermatology Summer Meeting; August 1-5, 2007; New York, NY.
47. Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50:16-22.
48. Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses (AK) on the head. Paper presented at: American Academy of Dermatology 68th Annual Meeting; March 5-9, 2010; Miami, FL.
49. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010-1019.
50. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001;48:751-755.
51. Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis [published online ahead of print July 1, 2008]. Br J Dermatol. 2008;159:205-210.
52. Hou Z, Sang S, You H, et al. Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res. 2005;65:8049-8056.
53. Green tea extract in treating patients with actinic keratosis. http://clinicaltrials.gov/ct2/show/NCT00005097?term=actinic+keratosis&rank=32. Published April 6, 2000. Updated October 11, 2010. Study terminated due to low conditional power for a positive study. Accessed April 20, 2012.
54. The efficacy and tolerability of Oleogel-S-10 in patients with actinic keratoses. http://clinicaltrials.gov/ct2/show/NCT00786994. Published November 5, 2008. Updated January 28, 2011. Accessed April 20, 2012.
55. Campione E, Diluvio L, Paternò EJ, et al. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11:45-50.
56. Study on the efficacy of LAS41005 in the treatment of actinic keratosis. http://clinicaltrials.gov/ct2/show/NCT00987246?term=las+41005&rank=1. Published September 29, 2009. Updated March 29, 2012. Accessed April 2, 2012.